{{--
  Back to User
--}}
{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode'])) Logout @endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
Back

A survey to collect the insights on challenges and management of uncontrolled Type 2 Diabetes from healthcare professionals (GEM IV Survey)

Survey Questionnaire Form
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif @if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

General Questions

  1. Based on your experience, what are the major changes you have observed in the prevalence of T2DM over past decade? What specific factors do you believe have contributed to these trends? *
  2. In your clinical practice, which age group do you find is most commonly affected by Type 2 Diabetes? *

  3. Which of the following are common comorbidities associated with diabetes in your opinion that increases the risk of complications? (Multiple options can be marked)*

  4. What are your primary treatment goals for T2DM patients? (Multiple options can be marked) *

  5. How frequently do you monitor HbA1c levels in your patients with Type 2 Diabetes? *

  6. Based on your professional experience, what do you consider to be the most significant unmet need in the management of Type 2 Diabetes? Please elaborate on why you believe this need is critical and how addressing it could improve patient outcomes. *
  7. Which is your preferred test for guiding T2DM treatment choice? *

  8. Which technology is increasingly used for continuous glucose monitoring in Type 2 Diabetes? *

  9. What is your first-line pharmacological therapy for newly diagnosed T2DM without complications? (Select all that apply) *

  10. Which factors most influence your drug choice? (Multiple options can be marked) *

  11. In treatment-naïve type 2 diabetes patients with HbA1c levels between 7.0-9.0%, which of the following initial therapeutic regimens do you consider optimal? *

  12. For patients diagnosed with HbA1c >9%, what is your initial approach? *

  13. How does the combination of Metformin and Glimepiride affect HbA1c levels compared to monotherapy?*

  14. What is the effect of adding Sitagliptin to a lower dose of Glimepiride? *

  15. What is the expected benefit of adding Sitagliptin in terms of β-cell function? *

  16. In your clinical practice, at what HbA1c level do you typically consider the starting doses of Metformin and Glimepiride when initiating combination therapy for Type 2 Diabetes patients? *
    17. HbA1c

  17. How do you manage patients who experience gastrointestinal side effects from immediate release metformin formulation? *

  18. What is your main concern when prescribing SUs? *

  19. For triple-drug therapy, which of the following Metformin-based regimens do you consider optimal for comprehensive glycemic and metabolic control? *

  20. In your opinion, which of the following monitoring parameters is essential when a patient is on a fixed-dose combination of Metformin, Glimepiride, and Sitagliptin? *

  21. What are the most notable benefits you have seen in patients using the combination of Metformin + Glimepiride + Sitagliptin compared to those on monotherapy or other combinations? *
  22. In real-world clinical settings, what percentage of patients achieve the target HbA1c goal with the combination of Metformin + Glimepiride + Sitagliptin? *

  23. If you prefer Metformin + Glimepiride + Sitagliptin combination, what is the typical reduction in HbA1c observed?

  24. In your experience what is the impact of early treatment intensification on long-term outcomes in T2DM? *

  25. What additional therapies do you consider if the triple combination therapy is insufficient? *

  26. Based on your clinical experience, how do you perceive the role of lifestyle modification in patients with Type 2 Diabetes Mellitus (T2DM)? Please elaborate on the specific lifestyle changes you recommend and their impact on patient outcomes. *
  27. From your experience, what steps should be taken in the event of a suspected adverse event with a triple fixed-dose combination (FDC) in diabetes treatment? How do you differentiate between adverse events? What management strategies do you use to address these adverse events? *
  28. In T2DM patients with CV disease, which drug class do you prefer adding? *

  29. How do you decide when to switch from oral therapy to insulin in patients on combination therapy? (Select as many as appropriate) *

  30. What is your overall experience with the dual combination therapy of glimepiride+ metformin in managing T2DM? *
  31. From your experience, why is the timing of administration important for oral antidiabetic drugs (OADs) from a patient's perspective? How do you educate your patients about the timing of OADs? *
  32. What are the main barriers to optimal treatment in your patients? *

  33. How do you tailor the management of diabetes for elderly patients (>65 years of age) with respect to combination of Metformin + Glimepiride + Sitagliptin? (Select as many as appropriate) *

  34. What advancements in diabetes research and treatment are you most excited about, and how do you think they will impact clinical practice? *
  35. Which guidelines do you primarily follow? *

  36. What do you prefer when HbA1c is ≥10% or if catabolic features are present? *

  37. After a patient with diabetes reaches their target HbA1c, how do you decide whether to continue, adjust, or reduce treatment? Please include any clinical reasoning or experiences where patient expectations influenced your approach.? *
  38. What methods do you use to enhance patient adherence to their treatment plans? (Select all that apply) *

  39. Based on your experience, could you provide detailed advice on the safety and potential risks of using a combination of metformin, glimepiride, and sitagliptin? *
  40. Which of the following is a potential future trend in Type 2 Diabetes management? *